Making a measurable differenceEliA CTD Screen, the most clinically relevant and reliable CTD Screen, helps simplify patient diagnosis

Streamlining connective tissue disease (CTD) diagnosticsThe EliA™ CTD Screen workflow can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1*,2**

EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8

90.4-93.4% negative1*, 2** Common panel

Refer to specialist

care

Complex case panels

EliA CTD Screen

EliA dsDNA test

EliA Mi-2 test

EliA Fibrillarin test

EliA PCNA test

EliA RNA Pol III test

EliA Rib-P test

EliA PM-Scl test

EliA Ro test

EliA La test

EliA U1RNP test

EliA Scl-70s test

EliA SmDp test

EliA Jo-1 test

EliA CENP test

Primary Differentiators

Secondary Differentiators

*Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen.**Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.

if from Primary Care

The superior specificity of EliA CTD Screen, based on 2,000 patients being tested, and a disease prevalence of 1%, leads to 158 fewer false positives per year.8

100

50

0EliA CTD Screen ANA IIF

92%84%

SensitivitySpecificity

90%76%

Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.

Study included unselected prospective study population of 322 patients suspected of systemic autoimmune rheumatic disease and a control group of 98 healthy blood donors. ANA measured by IIFA using INOVA Lite Hep-2 cells, according to manufacturers instructions using screening serum dilution of 1:80. EliA CTD Screen performed on Phadia 250 system.

*Prospective study of 9,856 patients tested by ANA IIF and EliA CTD Screen. **Prospective study of 1,708 patients rested by ANA IIF and EliA CTD Screen.

Simplifying laboratory life Optimised workflow – supporting your lean approach

Your partner – offering the complete support package to make the transition to EliA CTD Screen smooth

One operator, one footprint, one maintenance, one service programme, one solution for allergy and autoimmunity

No manual preparation necessary and with the flexibility to load and unload carriers

The same wash buffer, stop solution, development solution – improving cost and time efficiencies

One calibration curve per method stored for one month (IgG, IgM, IgA, IgE, calprotectin, anti-TSH-R) – maximising workflow efficiencies

Ability to run requests as and when they arriveHigh on-board carrier/test capacity

Ready to use carriers/reagents

System reagents are suitable for both EliA and ImmunoCAPTM tests

Efficient, flexible, calibration system

One system, one sample, multiple tests

Educational meetings for

your laboratory

Scientific support with results

interpretation

Letter for HCP to understand why/what has

changed

Support with educational

meetings for your clinical customers

Making a measurable differenceWhy choose Thermo Fisher Scientific as your partner in connective tissue disease diagnostics?

Streamlined diagnoses

EliA CTD Screen; a single test that includes 17 autoantibodies; can help simplify patient diagnosis, ruling out a CTD in up to 93.4% of tested patients1,2

Accurate results

EliA CTD Screen, validated in over 17k patients from different populations, provides you with comparable sensitivity and superior specificity to ANA IIF at various titres1-8

Efficient workflow

EliA CTD Screen is run on a fully automated, workflow optimised, Phadia™ Instrument, helping increase turnaround time in your laboratory

REFERENCES1. Willems P, et al. Clin Chem Lab Med 2018;56;909-18. 2. Robier C, et al. Clin Chem Lab Med 2016;54(8):1365-70.3. Korsholm T, et al. Scand J Rheumatol 2014;43:89. 4. Pereira LM, et al. EliA Journal 2010 (Special Edition 1):6-7.5. Alpini C, et al. EliA Journal 2010 (Special Edition 1):3.18. 6. Otten HG, et al. Clin Exp Rheumatol 2017.7. Jeong S, et al. PLoS ONE 2017;12(3). 8. van der Pol P, et al. Clinica Chimica Acta 2018;476:154-159.

Find out more at allergyai.com/uk/lab© 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 2019-26.AI.EU1.EN.v1.19